Abstract
BACKGROUND: Bile cytology has low diagnostic sensitivity and requires ancillary techniques. This study assessed the utility of enhancer of zeste homolog 2 (EZH2) immunocytochemistry (ICC) in bile cytology. METHODS: A total of 141 bile cytology specimens from 141 patients were evaluated retrospectively. Papanicolaou-stained slides were immunostained with an antibody to EZH2. After calculation of the EZH2 labeling index (LI), the cutoff value was determined via receiver operating characteristic curve analysis. Cytological performance with and without EZH2 ICC was evaluated with reference to the final diagnosis. RESULTS: The area under the curve for the EZH2 LI was 0.955, and the cutoff value for identifying benign bile samples versus malignant ones was 24.0%. The sensitivity and specificity values for malignancy were 53.4% and 100% for routine cytology only, 89.0% and 95.7% for EZH2 ICC only, and 89.8% and 95.7% for a combination of routine cytology and EZH2 ICC. The sensitivities of EZH2 ICC only and a combination of routine cytology and EZH2 ICC were significantly improved in comparison with routine cytology only (P
Author supplied keywords
Cite
CITATION STYLE
Tone, K., Ohno, S., Honda, M., Notsu, A., Sasaki, K., & Sugino, T. (2021). Application of enhancer of zeste homolog 2 immunocytochemistry to bile cytology. Cancer Cytopathology, 129(8), 612–621. https://doi.org/10.1002/cncy.22426
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.